Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
SSGJ -608- Psoriasis-II-01
Phase 2 small_molecule active
Quick answer
Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection for Psoriasis is a Phase 2 program (small_molecule) at Sunshine Biopharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sunshine Biopharma
- Indication
- Psoriasis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active